Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 14:365:l1628.
doi: 10.1136/bmj.l1628.

Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank

Hao Ma  1   2 , Xiang Li  1 , Dianjianyi Sun  1 , Tao Zhou  1 , Sylvia H Ley  1   3   4 , Jeanette Gustat  1 , Yoriko Heianza  1 , Lu Qi  5   3   4
Affiliations

Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank

Hao Ma et al. BMJ. .

Abstract

Objective: To prospectively assess the association of habitual glucosamine use with risk of cardiovascular disease (CVD) events.

Design: Prospective cohort study.

Setting: UK Biobank.

Participants: 466 039 participants without CVD at baseline who completed a questionnaire on supplement use, which included glucosamine. These participants were enrolled from 2006 to 2010 and were followed up to 2016.

Main outcome measures: Incident CVD events, including CVD death, coronary heart disease, and stroke.

Results: During a median follow-up of seven years, there were 10 204 incident CVD events, 3060 CVD deaths, 5745 coronary heart disease events, and 3263 stroke events. After adjustment for age, sex, body mass index, race, lifestyle factors, dietary intakes, drug use, and other supplement use, glucosamine use was associated with a significantly lower risk of total CVD events (hazard ratio 0.85, 95% confidence interval 0.80 to 0.90), CVD death (0.78, 0.70 to 0.87), coronary heart disease (0.82, 0.76 to 0.88), and stroke (0.91, 0.83 to 1.00).

Conclusion: Habitual use of glucosamine supplement to relieve osteoarthritis pain might also be related to lower risks of CVD events.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Association of glucosamine supplement use and risk of cardiovascular disease event and cardiovascular disease death stratified by potential risk factors. Results were adjusted for age, sex, race (white European, mixed, South Asian, black, others), average total annual household income (<£18 000, £18 000-£30 999, £31 000-£51 999, £52 000-£100 000, >£100 000, and “do not know” or missing; £1.00=$1.30, €1.20), alcohol intake, physical activity (<150 or ≥150 min/week), diabetes (yes, no, or missing), hypertension (yes or no), high cholesterol (yes or no), arthritis (yes or no), antihypertensive drugs (yes or no), lipid treatment (yes or no), insulin treatment (yes or no), aspirin use (yes or no), non-aspirin non-steroidal anti-inflammatory drug (NSAID) use (yes or no), vitamin supplement use (yes or no), mineral and other dietary supplement use (yes or no), and healthy diet (yes or no)
Fig 2
Fig 2
Association of glucosamine supplement use and risk of coronary heart disease and stroke stratified by potential risk factors. Results were adjusted for age, sex, race (white European, mixed, South Asian, black, others), average total annual household income (<£18 000, £18 000-£30 999, £31 000-£51 999, £52 000-£100 000, >£100 000, and “do not know” or missing; £1.00=$1.30, €1.20), alcohol intake, physical activity (<150 or ≥150 min/week), diabetes (yes, no, or missing), hypertension (yes or no), high cholesterol (yes or no), arthritis (yes or no), antihypertensive drugs (yes or no), lipid treatment (yes or no), insulin treatment (yes or no), aspirin use (yes or no), non-aspirin non-steroidal anti-inflammatory drug (NSAID) use (yes or no), vitamin supplement use (yes or no), mineral and other dietary supplement use (yes or no), and healthy diet (yes or no)
See this image and copyright information in PMC

References

    1. Jordan KM, Arden NK, Doherty M, et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT . EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55. 10.1136/ard.2003.011742 - DOI - PMC - PubMed
    1. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008;12:1-23. - PubMed
    1. Sibbritt D, Adams J, Lui CW, Broom A, Wardle J. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One 2012;7:e41540. 10.1371/journal.pone.0041540 - DOI - PMC - PubMed
    1. Clegg DO, Reda DJ, Harris CL, et al. . Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808. 10.1056/NEJMoa052771 - DOI - PubMed
    1. Wilkens P, Scheel IB, Grundnes O, Hellum C, Storheim K. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA 2010;304:45-52. 10.1001/jama.2010.893 - DOI - PubMed

Publication types